Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 8 Issue 2

Analytical Methods for the Assay of Efavirenz - A Review

Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India.

Received: January 22, 2024; Published: January 27, 2024

Abstract

Efavirenz is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In the present study the authors have summarised the analytical techniques so far developed for the estimation of Efavirenz in pharmaceutical formulations as well as the biological fluids.

Keywords: Efavirenz; Spectrophotometry; HPLC; HPTLC; LC-MS/MS

References

  1. Ruiz N. “Clinical history of Efavirenz”. International Journal of Clinical Practice 103 (1999): 3-7.
  2. Muni Bhaskar Reddy CR and Venkata Subbareddy GG. “UV-spectrophotometric method for estimation of Efavirenz in bulk and tablet dosage form”. International Journal of Pharmacal Sciences and Research12 (2012): 5033-5037.
  3. Srilatha P., et al. “Quantitative determination of Efavirenz in bulk drug and formulation by colorimetry”. Advances in Applied Science Research4 (2014): 176-180.
  4. Narasimha Rao BV., et al. “Method development and validation of Efavirenz by UV spectrophotometer”. IOSR Journal of Pharmacy and Biological Sciences1 (2020): 15-18.
  5. Deepan T., et al. “Spectroscopic determination of Efavirenz in bulk and pharmaceutical dosage form”. International Journal of Pharmacy and Medical Sciences1 (2015): 9-14.
  6. Ajit KN., et al. “Development and validation of UV spectrophotometric methods for estimation of Efavirenz in bulk and tablet dosage form”. Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry3 (2014): 134-144.
  7. Shweta Gupta., et al. “Development and validation of reversed phase HPLC gradient method for the estimation of Efavirenz in plasma”. PLoS ONE5 (2017): e0174777.
  8. Oksana IS., et al. “Development and validation of HPLC/UV-procedure for Efavirenz quantitative determination”. Journal of Pharmaceutical Sciences and Research11 (2018): 2829-2835.
  9. Paramita Saha and Murali Monohar Pandey. “Design of Experiment (DoE)-Approach based RP-HPLC analytical method development and validation for estimation of Efavirenz in bulk and formulations”. Journal of Chromatographic Science 1 (2022): 35-44.
  10. Vishal CG and Sanjaykumar BB. “Quantification and validation of stability-indicating RP-HPLC method for Efavirenz in bulk and tablet dosage form using Quality by Design (QbD): A Shifting Paradigm”. Journal of Chromatographic Science 2 (2022): 143-156.
  11. Sumanth KS., et al. “A new and precise bio-analytical method development and validation for the estimation of Efavirenz in human plasma by RP-HPLC”. International Journal of Pharmaceutical, Chemical and Biological Sciences3 (2019): 106-122.
  12. Osnir de Sá Viana., et al. “Development and validation of a HPLC analytical assay method for Efavirenz tablets: a medicine for HIV infections”. Brazilian Journal of Pharmaceutical Sciences 1 (2011): 97-102.
  13. Waghmare Santosh A and Kashid Arun M. “Reverse Phase-High Performance Liquid Chromatography method development and validation for estimation of Efavirenz by Quality by Design approach”. Journal of Drug Delivery and Therapeutics (1-s) (2019): 319-330.
  14. Ravisankar P., et al. “Novel analytical method development and validation for the quantitative analysis of Efavirenz in bulk and pharmaceutical dosage forms by RP-HPLC”. The Pharma Innovation Journal9 (2014): 32-39.
  15. Punam SD. “Development and validation of high-performance liquid chromatographic method for analysis of Efavirenz in capsule dosage form”. International Journal of Scientific Research in Science and Technology 5 (2019): 307-322.
  16. Emile Bienvenua., et al. “A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments”. Biomedical Chromatography11 (2013): 1554-1559.
  17. Purnima DH., et al. “Optimization and validation of RP-HPLC stability-indicating method for determination of Efavirenz and its degradation products”. International Journal of Applied Science and Engineering 2 (2010): 155-165.

Citation

Citation: Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna. “Analytical Methods for the Assay of Efavirenz - A Review".Acta Scientific Pharmaceutical Sciences 8.2 (2024): 61-63.

Copyright

Copyright: © 2024 Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US